yahoo_financeOriginal article
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Phase 2positivePositive
AI Analysis
Summary
Entrada Therapeutics' Independent Safety Data Monitoring Committee has recommended advancement to Cohort 2 of the ELEVATE-45-201 study at an increased dose of 10 mg/kg, indicating favorable safety profile in early trial results.
Clinical Trial Data
Phase
2
Outcome Details
Independent Safety Data Monitoring Committee recommends initiation of Cohort 2 at increased dose of 10 mg/kg
Importance:6/10
Sentiment:
0.70
clinical trialsafety monitoringdose escalationELEVATE-45-201
Related Companies
Read the original article
Published by yahoo_finance on June 2, 2026 11:00 AM